A Multicenter Clinical Trial to Evaluate the Feasibility and Outcome of Same-day Antiretroviral Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) Among Patients Testing Positive by HIV Confirmatory Tests
Latest Information Update: 06 Feb 2023
Price :
$35 *
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 06 Feb 2023 Last checked against ClinicalTrials.gov: US record.
- 20 Jan 2021 New trial record